Clinical & Experimental Metastasis

, Volume 19, Issue 6, pp 477–486

Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma

  • Kenji Kimura
  • Tetsuhiro Nakano
  • Yong-Bum Park
  • Masachika Tani
  • Hiroyuki Tsuda
  • Yasuo Beppu
  • Hideshige Moriya
  • Jun Yokota
Article

Abstract

Relevant animal models for metastasis of osteosarcoma is needed to understand the biology and to develop the treatment modality of metastasis of human osteosarcoma. Therefore, we screened six human osteosarcoma cell lines for metastatic ability in nude mice. The HuO9 cell line was identified as being metastatic to the lung after intravenous injection. We established two sublines, HuO9-M112 and HuO9-M132, with high metastatic potential to the lung from the parental HuO9 cells by in vivo selection. There were no differences between these two sublines and the parental cells in the growth rate in vitro and the tumorigenicity after subcutaneous injection in nude mice, however, mice injected with the metastatic sublines became moribund earlier than mice injected with the parental HuO9 cells did. Thus, adriamycin (ADR) and recombinant interleukin-12 (IL-12) were administered to mice injected with the HuO9-M112 subline to suppress experimental lung metastases. Production of lung colonies was significantly suppressed and the prognoses of mice were significantly improved by both ADR and IL-12 treatments. These results indicate that both ADR and IL-12 are effective agents against pulmonary metastatic osteosarcoma, and that these sublines are useful for studies on the biological behavior and treatment of pulmonary metastatic osteosarcoma.

adriamycin human osteosarcoma cell line in vivo selection interleukin-12 lung metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Eilber F, Giuliano A, Eckardt J et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5: 21–6.PubMedGoogle Scholar
  3. 3.
    Supplementary information is available at http://cancernet.nci.nih.gov/Cancer_Types/Osteosarcoma.shtmlGoogle Scholar
  4. 4.
    Meyers PA, Heller G, Healey J et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5–15.PubMedGoogle Scholar
  5. 5.
    Souhami RL, Craft AW, Eijken V et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76–84.PubMedGoogle Scholar
  7. 7.
    Khanna C, Prehn J, Yeung C et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000; 18: 261–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Mori S, Ueda T, Kuratsu S et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1998; 61: 148–52.Google Scholar
  9. 9.
    Asai T, Ueda T, Itoh K et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1995; 76: 418–22.CrossRefGoogle Scholar
  10. 10.
    Honoki K, Tsutsumi M, Miyauchi Y et al. Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA isassociated with spontaneous lung metastas is in rat-transplantable osteosarcomas. Cancer Res 1993; 53: 5038–42.PubMedGoogle Scholar
  11. 11.
    Honoki K, Mori T, Tsutsumi M et al. Heterogeneous pattern of gene expression in cloned cell lines established from a rat transplantable osteosarcoma lung metastatic nodule. Cancer Lett 1998; 127: 221–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Barroga EF, Kadosawa T, Okumura M et al. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999; 61: 361–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Vihinen P, Riikonen T, Laine A et al. Integrin α2β1 in tumorigenic human osteosarcoma cell lines regulates cell adhesion, migration, and invasion by interaction with type I collagen. Cell Growth Differ. 1996; 7: 439–47.PubMedGoogle Scholar
  14. 14.
    Scotlandi K, Manara MC, Serra M et al. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999; 18: 739–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17: 501–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Berlin O, Samid D, Donthineni-Rao R et al. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 1993; 53: 4890–5.PubMedGoogle Scholar
  17. 17.
    Meyer WH, Houghton JA, Houghton PJ et al. Development and characterization of pediatric osteosarcoma xenografts. Cancer Res 1990; 50: 2781–5.PubMedGoogle Scholar
  18. 18.
    Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986; 5: 29–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Fidler IJ. Selection of successive tumour lines for metastasis. Nature 1973; 242: 148–9.Google Scholar
  20. 20.
    Kawai A, Ozaki T, Ikeda S et al. Two distinct cell lines derived from a human osteosarcoma. J Cancer Res Clin Oncol 1989; 115: 531–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Kawai A. A newly established human osteosarcoma cell line with osteoblastic properties. Clin Orthop 1990; 259: 256–67.PubMedGoogle Scholar
  22. 22.
    Ookawa K, Tsuchida S, Adachi J et al. Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line. Oncogene 1997; 14: 1389–96.PubMedCrossRefGoogle Scholar
  23. 23.
    Wong IHN, Chan AT, Johnson PJ. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: A pilot study. Clin Cancer Res 2000; 6: 2183–8.PubMedGoogle Scholar
  24. 24.
    Ogose A, Motoyama T, Hotta T et al. Expression of bone morphogenetic proteins in human osteogenic and epithelial tumor cells. Pathol Int 1996; 46: 9–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Kjonniksen I, Winderen M, Bruland O et al. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res 1994; 54: 1715–9.PubMedGoogle Scholar
  26. 26.
    Worth LL, Jia SF, Zhou Z et al. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 2000; 6: 3713–8.PubMedGoogle Scholar
  27. 27.
    Miller CW, Aslo A, Won A et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996; 122: 559–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Nielsen GP, Burns KL, Rosenberg AE et al. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 1998; 153: 159–63.PubMedGoogle Scholar
  29. 29.
    Yokota J, Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J 1993; 7: 920–5.PubMedGoogle Scholar
  30. 30.
    Park YB, Park MJ, Kimura K et al. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet, in press.Google Scholar
  31. 31.
    Urst MR, DeLange RJ, Finerman GA. Bone cell differentiation and growth factors. Science 1983; 220: 680–6.Google Scholar
  32. 32.
    Roden GA, Noda M. Gene expression in osteoblastic cells. Cirt Rev Eukaryot Gene Expr 1991; 1: 85–98.Google Scholar
  33. 33.
    Yoshikawa H, Rettig WJ, Takaoka K et al. Expression of bone morphogenetic proteins in human osteosarcoma. Cancer 1994; 73: 85–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61–85.PubMedGoogle Scholar
  35. 35.
    Khanna C, Khan J, Nguyen P et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001; 61: 3750–9.PubMedGoogle Scholar
  36. 36.
    Gubler U, Chua AO, Schoenhaut DS et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Wolf SF, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074–81.PubMedGoogle Scholar
  38. 38.
    Gately MK, Gubler U, Brunda MJ et al. Interleukin-12: A cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1994; 1: 187–96.PubMedGoogle Scholar
  39. 39.
    Mocellin S, Wang E, Marincola FM et al. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24: 392–407.CrossRefGoogle Scholar
  40. 40.
    Cui J, Shin T, Kawano T et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Takeda K, Hayakawa Y, Atsuta M et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 2000; 12: 909–14.PubMedCrossRefGoogle Scholar
  42. 42.
    Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165: 2665–70.PubMedGoogle Scholar
  43. 43.
    Voest EE, Kenyon BM, O'Reilly KM et al. J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581–6.PubMedGoogle Scholar
  44. 44.
    Duda DG, Sunamura M, Lozonschi L et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111–6.PubMedGoogle Scholar
  45. 45.
    Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223–30.PubMedCrossRefGoogle Scholar
  46. 46.
    Verbik DJ, Stinson WW, Brunda MJ et al. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Exp Metastasis 1996; 14: 219–29.PubMedGoogle Scholar
  47. 47.
    Mu J, Zou JP, Yamamoto N et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404–8.PubMedGoogle Scholar
  48. 48.
    Cavallo F, Carlo E, Butera M et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 1999; 59: 414–21.PubMedGoogle Scholar
  49. 49.
    Eberl G, Lees R, Smiley ST et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NKT cells. J Immunol 1999; 162: 6410–9.PubMedGoogle Scholar
  50. 50.
    Al-Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 2000; 6: 100–2.PubMedCrossRefGoogle Scholar
  51. 51.
    Ito S, Nakanishi H, Ikehara Y et al. Real-time observation of micrometastasis formation in the living mouse liver using a green fluorescent protein gene-tagged rat tongue carcinoma cell line. Int J Cancer 2001; 93: 212–7.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Kenji Kimura
    • 1
    • 2
  • Tetsuhiro Nakano
    • 1
  • Yong-Bum Park
    • 1
  • Masachika Tani
    • 1
  • Hiroyuki Tsuda
    • 3
  • Yasuo Beppu
    • 4
  • Hideshige Moriya
    • 2
  • Jun Yokota
    • 1
  1. 1.Biology and Chemotherapy DivisionsNational Cancer Center Research InstituteTokyoJapan
  2. 2.Department of Orthopedic SurgeryChiba UniversityChibaJapan
  3. 3.Experimental Pathology and Chemotherapy DivisionsNational Cancer Center Research InstituteTokyoJapan
  4. 4.Orthopedic DivisionNational Cancer Center HospitalTokyoJapan
  5. 5.Biology DivisionNational Cancer Center Research InstituteTokyoJapan

Personalised recommendations